drugset / Trial / NCT01183533
Safety of Intravenous Thrombolysis for Wake-up Stroke
Phase 2
Completed
40 enrolled
The University of Texas Health Science Center, Houston
Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose is to demonstrate the safety of intravenous tissue plasminogen activator (IV t-PA) in ischemic stroke patients who present to the emergency department (ED) after awakening with the symptoms of suspected ischemic stroke.
Timeline
- Start
- 2010-07
- Primary completion
- 2013-10
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alteplase | Protein / enzyme biologic | 0.9 mg/kg | Intravenous |